Sotalol (hydrochloride)

Sotalol hydrochloride (MJ 1999) is an orally active, non-selective β-adrenergic receptor blocker. Sotalol hydrochloride is a potent antiarrhythmic agent that can be used for the research of pediatric arrhythmias. Sotalol hydrochloride blocks β-receptors, and potassium KCNH2 channels. Antiepileptic Agent[1][2][3].

Product Specifications

CAS Number

[959-24-0]

Product Name Alternative

MJ 1999

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Adrenergic Receptor; Potassium Channel

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Sotalol-hydrochloride.html

Purity

99.93

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

OC(C1=CC=C(NS(C)(=O)=O)C=C1)CNC(C)C.Cl

Molecular Formula

C12H21ClN2O3S

Molecular Weight

308.82

Precautions

H315, H319, H335

References & Citations

[1]Marta Reyes-Corral, et al. Differential Free Intracellular Calcium Release by Class II Antiarrhythmics in Cancer Cell Lines. J Pharmacol Exp Ther. 2019 Apr;369 (1) :152-162.|[2]Xiaomei Li, et al. Pediatric Dosing of Intravenous Sotalol Based on Body Surface Area in Patients with Arrhythmia. Pediatr Cardiol. 2017 Oct;38 (7) :1450-1455.|[3]Kinga K Borowicz-Reutt, et al. Sotalol does not interfere with the antielectroshock action of selected second-generation antiepileptic drugs in mice.Pharmacol Rep. 2021 Apr;73 (2) :516-524.